SCHEMBL7725810

SCHEMBL7725810

CCCN(O)c1cccc2c1CCCC2

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 1/20 0.46
RXRB P28702 1/20 0.46
RXRG P48443 1/20 0.46
ALDH1A1 P00352 3/20 0.44
LMNA P02545 2/20 0.44
BCL2L1 Q07817 1/20 0.44
BAD Q92934 1/20 0.44
MEN1 O00255 1/20 0.44
THRA P10827 1/20 0.44
THRB P10828 1/20 0.44
KMT2A Q03164 1/20 0.44
DRD3 P35462 3/20 0.41
HTR1A P08908 3/20 0.40
HTR7 P34969 3/20 0.40
DRD2 P14416 2/20 0.40
HTR1D P28221 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2D6 P10635 1/20 0.40
TSHR P16473 1/20 0.40
HTR1B P28222 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19697741 0.76 RXRA (0.47) RXRARXRBRXRGALDH1A1LMNA
SCHEMBL3365242 0.73 RXRA (0.50) RXRARXRBRXRGALDH1A1LMNA
SCHEMBL16559080 0.73 RXRA (0.47) RXRARXRBRXRGALDH1A1LMNA
SCHEMBL9092770 0.72 RXRA (0.53) RXRARXRBRXRGALDH1A1LMNA
SCHEMBL26107653 0.70 TRPA1 (0.39) ALDH1A1LMNAMEN1KMT2ATSHR
SCHEMBL16577649 0.70 RXRA (0.45) RXRARXRBRXRGALDH1A1LMNA
SCHEMBL24114484 0.70 RXRA (0.43) RXRARXRBRXRGALDH1A1LMNA
SCHEMBL8887944 0.70 RXRA (0.45) RXRARXRBRXRGALDH1A1LMNA
SCHEMBL15465888 0.70 RXRA (0.50) RXRARXRBRXRGALDH1A1BCL2L1
SCHEMBL28747345 0.70 ESR1 (0.44) ALDH1A1LMNAMEN1KMT2AHTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6372920-B1 ALKYLATING 2-AMINOTETRALIN IN PRESENCE OF BASE SELECTED FROM ALKALI METAL CARBONATES AND BICARBONATES, WHEREIN AMOUNT OF BASE IS LESS THAN ABOUT 1.9-FOLD MOLAR EXCESS WITH RESPECT TO AMOUNT OF 2-AMINOTETRALIN ADERIS PHARMACEUTICALS, INC. 2002-04-16 US disclosed